EA201890160A1 - Твердые фармацевтические композиции для лечения вируса гепатита с - Google Patents

Твердые фармацевтические композиции для лечения вируса гепатита с

Info

Publication number
EA201890160A1
EA201890160A1 EA201890160A EA201890160A EA201890160A1 EA 201890160 A1 EA201890160 A1 EA 201890160A1 EA 201890160 A EA201890160 A EA 201890160A EA 201890160 A EA201890160 A EA 201890160A EA 201890160 A1 EA201890160 A1 EA 201890160A1
Authority
EA
Eurasian Patent Office
Prior art keywords
solid pharmaceutical
pharmaceutical compositions
pharmaceutically acceptable
hepatitis
virus
Prior art date
Application number
EA201890160A
Other languages
English (en)
Inventor
Нэнси Сивер
Ульрих Вестедт
Уте Ландер
Катрин Шнайдер
Бенедикт Штайц
Томас Мюллер
Регина Ройль
Констанце Обермиллер
Адивараха Джаясанкар
Михель Зимон
И Гао
Харальд Хах
Самуэль Киерематенг
Катарина Асмус
Пин Тун
Дунхуа Чжу
Мариус Нарис
Коллин Гарретт
Original Assignee
Эббви Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эббви Инк. filed Critical Эббви Инк.
Publication of EA201890160A1 publication Critical patent/EA201890160A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение обеспечивает твердые фармацевтические композиции, содержащие соединение 1 и соединение 2. В одном варианте осуществления твердая фармацевтическая композиция содержит (1) первый слой, который содержит 100 мг соединения 1, а также фармацевтически приемлемый гидрофильный полимер и фармацевтически приемлемое поверхностно-активное вещество, все из них составлены в аморфную твердую дисперсию; и (2) второй слой, который содержит 40 мг соединения 2, а также фармацевтически приемлемый гидрофильный полимер и фармацевтически приемлемое поверхностно-активное вещество, все из них составлены в аморфную твердую дисперсию.
EA201890160A 2015-06-26 2016-06-24 Твердые фармацевтические композиции для лечения вируса гепатита с EA201890160A1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562185145P 2015-06-26 2015-06-26
US201562186154P 2015-06-29 2015-06-29
US201562193639P 2015-07-17 2015-07-17
US201662295309P 2016-02-15 2016-02-15
PCT/US2016/039266 WO2016210273A1 (en) 2015-06-26 2016-06-24 Solid pharmaceutical compositions for treating hcv

Publications (1)

Publication Number Publication Date
EA201890160A1 true EA201890160A1 (ru) 2018-06-29

Family

ID=56409187

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890160A EA201890160A1 (ru) 2015-06-26 2016-06-24 Твердые фармацевтические композиции для лечения вируса гепатита с

Country Status (24)

Country Link
US (3) US20160375087A1 (ru)
EP (1) EP3313378A1 (ru)
JP (2) JP7162425B2 (ru)
KR (1) KR102637828B1 (ru)
CN (1) CN107920996A (ru)
AU (1) AU2016283018C1 (ru)
BR (1) BR112017028185A2 (ru)
CA (1) CA2990855A1 (ru)
CL (1) CL2017003350A1 (ru)
CO (1) CO2017013305A2 (ru)
CR (1) CR20180030A (ru)
DO (1) DOP2017000314A (ru)
EA (1) EA201890160A1 (ru)
EC (1) ECSP18000689A (ru)
HK (1) HK1250627A1 (ru)
IL (1) IL256504B (ru)
MX (1) MX2018000218A (ru)
MY (1) MY192606A (ru)
PE (1) PE20180488A1 (ru)
PH (1) PH12017502426A1 (ru)
RU (2) RU2018102809A (ru)
SG (1) SG10202002899VA (ru)
WO (1) WO2016210273A1 (ru)
ZA (1) ZA201800533B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
RU2018105849A (ru) * 2015-07-17 2019-08-19 Эббви Инк. Твердые фармацевтические композиции для лечения вируса гепатита с
GB202113944D0 (en) * 2021-09-29 2021-11-10 Univ Liverpool Injectable formulations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087386A (en) * 1996-06-24 2000-07-11 Merck & Co., Inc. Composition of enalapril and losartan
DE102004008804A1 (de) * 2004-02-20 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mehrschichttablette
ES2300188B1 (es) * 2006-05-24 2009-05-01 Ferrer Internacional, S.A. Comprimido bicapa para la prevencion de los accidentes cardiovasculares.
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
SG10201702522UA (en) * 2009-06-11 2017-05-30 Abbvie Bahamas Ltd Anti-viral compounds to treat hcv infection
US8716454B2 (en) * 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
LT2498758T (lt) * 2009-11-13 2018-11-26 Astrazeneca Ab Dvisluoksnės tabletės formuluotės
NZ605440A (en) * 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
WO2012040167A1 (en) 2010-09-21 2012-03-29 Enanta Pharmaceuticals, Inc. Macrocyclic proline derived hcv serine protease inhibitors
DK2897611T3 (da) * 2012-09-18 2019-11-04 Abbvie Inc Fremgangsmåder til behandling af hepatitis c
US20140275099A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Methods for treating hcv

Also Published As

Publication number Publication date
CN107920996A (zh) 2018-04-17
MY192606A (en) 2022-08-29
ZA201800533B (en) 2018-12-19
CL2017003350A1 (es) 2018-06-22
JP2022177014A (ja) 2022-11-30
KR102637828B1 (ko) 2024-02-20
AU2016283018B2 (en) 2021-10-07
DOP2017000314A (es) 2018-02-15
IL256504A (en) 2018-02-28
ECSP18000689A (es) 2018-03-31
RU2018102809A3 (ru) 2019-12-10
US20190216882A1 (en) 2019-07-18
PE20180488A1 (es) 2018-03-07
PH12017502426A1 (en) 2018-07-02
EP3313378A1 (en) 2018-05-02
JP2018518517A (ja) 2018-07-12
US20160375087A1 (en) 2016-12-29
SG10202002899VA (en) 2020-05-28
AU2016283018C1 (en) 2022-03-03
IL256504B (en) 2021-09-30
CA2990855A1 (en) 2016-12-29
HK1250627A1 (zh) 2019-01-11
MX2018000218A (es) 2018-03-08
AU2016283018A1 (en) 2018-01-25
KR20180021840A (ko) 2018-03-05
RU2021102950A (ru) 2021-03-01
JP7162425B2 (ja) 2022-10-28
CO2017013305A2 (es) 2018-05-21
US20200282004A1 (en) 2020-09-10
RU2018102809A (ru) 2019-07-29
CR20180030A (es) 2018-05-24
WO2016210273A1 (en) 2016-12-29
BR112017028185A2 (pt) 2018-09-04

Similar Documents

Publication Publication Date Title
EA201890736A1 (ru) Модуляторы корового белка вируса гепатита b
CL2016002179A1 (es) Nuevas heteroarildihidropirimidinas 6-fusionadas para el tratamiento y la profilaxis de la infección por virus de la hepatitis b.
EA201691448A1 (ru) Гибридосомы, содержащие их композиции, способы их получения и их применения
EA201790630A1 (ru) Способы получения рибозидов
EA201691261A1 (ru) Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b
EA201592126A1 (ru) 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
EA201791256A1 (ru) Производные хиназолина, применяемые для лечения вич
MX2022000453A (es) Compuestos útiles para tratar infecciones por virus de influenza.
CL2012002355A1 (es) Compuestos derivados de 1,3,4,8-tetrahidro-2h-pirido[1,2-a]pirazina; composicion farmaceutica que los comprende; kit farmaceutico; y su uso como inhibidores de la integrasa del vih para el tratamiento de una enfermedad infecciosa del vih.
EA201391152A1 (ru) Ингибиторы вируса гепатита с
EA200970916A1 (ru) Соединения 5,6-дигидро-1н-пиридин-2-она
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
EA201490222A1 (ru) Комбинированные составы на основе дарунавира
EA202091337A1 (ru) Ингибиторы гистонацетилтрансфераз семейства myst
EA202192786A1 (ru) Твердые формы (e)-3-[2-(2-тиенил)винил]-1h-пиразола
EA201890160A1 (ru) Твердые фармацевтические композиции для лечения вируса гепатита с
EA201591717A1 (ru) Твердые формы гидрохлорида вемурафениба
EA201890334A1 (ru) Твердые фармацевтические композиции для лечения вируса гепатита с
EA201792094A1 (ru) Ингибиторы полимеразы вируса гепатита c
PH12021551058A1 (en) Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof
EA201892376A1 (ru) Комбинированный состав трех противовирусных соединений
EA201891680A1 (ru) Производные индана в качестве модуляторов mglur7
EA201791218A1 (ru) Композиция, содержащая ванкомицин и орлистат
EA202191343A1 (ru) Антибиотические соединения, способы их получения, фармацевтические композиции, содержащие их, и их применение
EA202092930A1 (ru) Модуляторы сборки капсида вируса гепатита b